NIKKEI 225
38,106.41 -708.15 (-1.82%) HANG SENG
18,075.56 +133.78 (+0.75%) CRUDE OIL
78.30 -0.15 (-0.19%) GOLD FUTURES
2,338.50 -10.60 (-0.45%) DOW
38,589.16 -57.94 (-0.15%) Bitcoin GBP
52,306.02 +201.16 (+0.39%)
APLS Jul 2024 55.000 put
| Previous close | 14.10 |
| Open | 14.10 |
| Bid | 12.60 |
| Ask | 13.90 |
| Strike | 55.00 |
| Expiry date | 2024-07-19 |
| Day's range | 14.10 - 14.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.08k |
ZacksApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
GlobeNewswireSYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE® (pegcetacoplan injection) preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These positive data from the GALE long-term ext
ZacksWhy Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
